Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective evaluation of topical hydrocortisone in dry eye with meibomian gland dysfunction
2021-003469-36Phase 4Active
- Sponsor
- Laboratoires Théa
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydrocortisone in dry eye syndrome (DED) and meibomian gland dysfunction (MGD) (2 arms), sponsored by Laboratoires Théa. Started Jul 2021; status: active.
02
Drugs
hydrocortisone
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on 2021-003469-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003469-36.